Next Article in Journal
Identification of a Novel Neuropeptide S Receptor Antagonist Scaffold Based on the SHA-68 Core
Previous Article in Journal
New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress
Previous Article in Special Issue
Combination Therapies with PRRT
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 14
Issue 10
10.3390/ph14101022
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE

by
Amir Sabet
1,*,
Nicolai Mader
1,
Jörg Thomas Bittenbring
2,
Fadi Khreish
3,
Frank Grünwald
1,
Hans Jürgen Biersack
4 and
Samer Ezziddin
3
1
Department of Nuclear Medicine, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany
2
Department of Haematology and Oncology, Caritas Hospital Saarbrücken, 66123 Saarbrücken, Germany
3
Department of Nuclear Medicine, Saarland University Medical Center, 66421 Homburg, Germany
4
Department of Nuclear Medicine, University Hospital Bonn, 53127 Bonn, Germany
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2021, 14(10), 1022; https://doi.org/10.3390/ph14101022
Submission received: 16 July 2021 / Revised: 20 September 2021 / Accepted: 27 September 2021 / Published: 5 October 2021
(This article belongs to the Special Issue Advances in Peptide Receptor Radionuclide Therapy)
Browse Figure
Versions Notes

Abstract

:
Peptide receptor radionuclide therapy (PRRT) of metastatic neuroendocrine tumors (NET) can be successfully repeated but may eventually be dose-limited. Since 177Lu-DOTATATE dose limitation may come from hematological rather than renal function, hematological peripheral blood stem cell backup might be desirable. Here, we report our initial experience of peripheral blood stem-cell collection (PBSC) in patients with treatment-related cytopenia and therefore high risk of bone-marrow failure. Five patients with diffuse bone-marrow infiltration of NET and relevant myelosuppression (≥grade 2) received PBSC before one PRRT cycle with 177Lu-DOTATATE (7.6 ± 0.8 GBq/cycle). Standard stem-cell mobilization with Granulocyte-colony stimulating factor (G-CSF) was applied, and successful PBSC was defined as a collection of >2 × 106/kg CD34+ cells. In case of initial failure, Plerixafor was administered in addition to G-CSF prior to apheresis. PBSC was successfully performed in all patients with no adverse events. Median cumulative activity was 44.8 GBq (range, 21.3–62.4). Three patients had been previously treated with PRRT, two of which needed the addition of Plerixafor for stem-cell mobilization. Only one of five patients required autologous peripheral blood stem-cell transplantation during the median follow up time of 28 months. PBSC collection seems to be feasible in NET with bone-marrow involvement and might be worth considering as a backup strategy prior to PRRT, in order to overcome dose-limiting bone-marrow toxicity.

1. Introduction

Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is a longstanding systemic treatment for metastatic gastroenteropancreatic neuroendocrine tumors (GEP- NET) [1,2,3]. Over recent years, several studies have reported remarkable results of individualized PRRT schemes for selected patients in different settings [4,5,6,7,8,9,10,11,12,13,14]. However, the only conducted randomized phase III trial (NETTER-1) demonstrating the efficacy of PRRT was limited to patients with midgut NET receiving a “standard treatment scheme” consisting of four cycles with a predefined administered activity of 7.4 GBq per cycle every 8 weeks [15]. Therefore, identifying other eligible patients for PRRT, appropriate treatment individualizations, and baseline characteristics influencing the outcome mainly relies on data from retrospective studies [16,17,18,19,20]. To date, ki67-index <20% and limited liver tumor burden are considered as the main favorable prognostic factors for NET patients undergoing PRRT, irrespective of the primary tumor [8,21,22]. Patients with advanced metastatic bone involvement, on the other hand, are at higher risk of bone-marrow impairment and are treated cautiously to avoid severe irreversible myelotoxicity [23,24,25]. In view of the low overall toxicity of PRRT, especially the low nephrotoxic potential of 177Lu-DOTATATE, myelosuppression may also be the cumulative dose-limiting toxicity in responsive patients, restricting the application of repeat PRRT cycles [2,26,27,28].
Autologous peripheral blood stem-cell transplantation is widely used after myeloablative treatments in a variety of hematological malignancies and solid tumors. Peripheral blood is the usual source of stem cells, providing a safe and easily accessible route for isolating autologous stem cells [29,30]. Different strategies have been applied to optimize the mobilization and collection of peripheral blood stem cells (PBSC), especially in patients with risk factors for poor mobilization such as bone-marrow involvement [31,32]. To the best of our knowledge, this concept has not yet been considered for PRRT and it remains unclear whether PBSC can be collected in bone metastatic NET disease. If proven successful and safe, autologous transplantation of PBSC may encourage the use of higher activities and more cycles, especially in patients with advanced metastatic disease and very few therapeutic options, increasing the clinical benefit and expanding the indications for PRRT. In this paper we introduce and discuss the feasibility of PBSC collection in NET patients with metastatic bone-marrow spread.

2. Methods

Five patients with bone-marrow infiltration of NET and cytopenia on complete blood counts (≥grade 2 according to CTCAE v5.0) received PBSC apheresis 8 ± 4 weeks before the onset (n = 2) or in the interval of two 177Lu-DOTATATE administrations (n = 3). PRRT was performed with 7.6 ± 0.8 GBq 177Lu-DOTATATE per cycle at standard intervals of 3 months using a previously described protocol [22]. Prior to PBSC, standard stem-cell mobilizing agent granulocyte-colony stimulating factor (G-CSF) was applied subcutaneously at 10 µg/kg/day for at least 4 days to achieve CD34+ cell counts ≥ 10/µL as the prerequisite for the apheresis. Successful PBSC was defined as >2 × 106/kg CD34+ cells [31]. If adequate numbers of stem cells could not be mobilized, the selective CXCR4 antagonist Plerixafor was added to G-CSF to enhance the outcome (2,40 mg/kg s.c.,10 h before apheresis) [32,33]. Table 1 provides tumor- and treatment-related characteristics of the patient cohort.

3. Results

All patients had relevant cytopenia (≥grade II) of at least one blood cell line at the time of apheresis. Three patients had anemia (two grade II, and one grade III), two patients had thrombocytopenia (one grade III, and one grade IV), and three patients had leukopenia (one grade II, and two grade III). The median cumulative activity of 177Lu-DOTATATE was 44.8 GBq (range, 21.3–62.4; mean, 42.1). PBSC was successfully performed in all five patients. Two of three patients with progressive disease under chemotherapy showed relevant cytopenia at baseline and received PBSC prior to initiation of PRRT, adequate mobilization was achieved in both with G-CSF only. In contrast, two of three patients previously treated with PRRT required additional Plerixafor to achieve >2 × 106/kg CD34+ cells. During the mean follow-up of 28 months, one patient required autologous stem-cell support because of severe cytopenia (thrombocytopenia, grade IV; neutropenia, grade III) 70 days after the completion of PRRT. Blood counts recovered to near normal (grade I thrombocytopenia, normal neutrophil and leukocyte counts) 6 weeks after the procedure. In the other four patients, the harvested PBSC remained stored as back-up material in case of future bone-marrow failure. Figure 1 illustrates 68Ga-DOTATOC PET images of a patient with renal NET treated with 29 GBq 177Lu-DOTATATE prior to PBSC harvesting.

4. Discussion

This preliminary report introduces the concept of PBSC in high-risk patients with advanced bone-marrow involvement of NET undergoing PRRT, describing a successful procedure in five patients with bone-marrow impairment at the time of apheresis.
Few therapeutic options exist for patients with advanced stage metastatic NET. PRRT with 177Lu-DOTATATE is a potent systemic treatment modality for metastatic NET with a low overall toxicity profile. However, the risk of therapy-induced bone-marrow failure restricts the application of sufficiently high activities in patients with extensive bone-marrow infiltration. Similarly, patients with low or decreasing hematological parameters are generally treated with reduced activities, leading to suboptimal treatment outcomes in patients with high tumor load or a clinical need for tumor remission. Patients with significant cytopenia of ≥grade III are often discarded from PRRT [23,25,34]. For a substantial portion of patients with metastatic NET undergoing PRRT, it may persist as a long-term palliative treatment as it can reinduce tumor response once re-progression occurred [16,35,36,37]. However, cumulative absorbed dose to bone marrow would eventually limit the application [38,39]. Moreover, long survival of NET patients allows for the clinical occurrence of myelodysplastic syndrome, a potential late sequel of alkylating chemotherapy and systemic radionuclide therapies [40].
If proved feasible in clinical practice, autologous transplantation of PBSC may contribute to overcome the dose-limiting hematotoxicity, allowing dose escalations or repeat PRRT cycles in selected patients. This approach has been successfully used in patients with malignant pheochromocytomas and paragangliomas treated with 131I-Metaiodobenzylguanidine (131I-MIBG). In a phase II study by Fitzgerald et al., PBSC collection at baseline enabled an individualized high-dose treatment with a mean of 833 mCi (557–1185 mCi) in 30 patients. In 4/30 patients, bone-marrow support was needed after the treatment and effectively prevented irreversible myelosuppression [41]. Similarly, in our series, blood counts of the patient with severe cytopenia recovered after autologous peripheral blood stem-cell transplantation.
Hematopoietic growth factors like G-CSF are used for releasing stem cells from the bone marrow into the peripheral blood. The selective CXCR4 antagonist AMD3100 (Plerixafor) [42,43], has been proven to enhance PBSC collection in cancer patients and is established for this purpose, especially in case of mobilization issues [33]. Plerixafor was used in two of our patients to achieve sufficient cell mobilization. Therefore, the most appropriate time point for prophylactic PBSC remains to be determined. Although PBSC would possibly be easier prior to initiation of PRRT [32], collection at later time points (e.g., after two cycles) may facilitate the assessment of risk for developing bone-marrow failure under therapy. In our small cohort, successful PBSC was possible in all patients even after high cumulative activities of 177Lu-DOTATATE.

5. Conclusions

Prophylactic PBSC seems technically feasible in patients with advanced bone metastatic NET, even after PRRT with high cumulative activity. The procedure might be worth considering especially in high-risk candidates in an attempt to overcome the dose-limiting hematological toxicity of PRRT.

Author Contributions

Conception of the study: S.E., A.S.; Collection and assembly of data: N.M.; Interpretation of data: J.T.B., A.S.; Drafting of the article: A.S.; Enhancing intellectual content: F.K., H.J.B.; Critical revision of the article for important intellectual content: S.E., N.M., J.T.B., F.G. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This article does not describe any studies with animals performed by any of the authors. Consent was obtained from all individual participants included in the study.

Informed Consent Statement

Consent was obtained from all individual participants included in the study.

Data Availability Statement

Data is contained within the article.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

177LuLutetium-177
CTCAECommon Terminology Criteria for Adverse Events
G-CSFGranulocyte-colony stimulating factor
NETNeuroendocrine tumor
PBSCPeripheral blood stem-cells collection
PRRTPeptide receptor radionuclide therapy

References

  1. Kwekkeboom, D.J.; de Herder, W.W.; Kam, B.L.; van Eijck, C.H.; van Essen, M.; Kooij, P.P.; Feelders, R.A.; van Aken, M.O.; Krenning, E.P. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival. J. Clin. Oncol. 2008, 26, 2124–2130. [Google Scholar] [CrossRef] [Green Version]
  2. Bodei, L.; Kidd, M.; Paganelli, G.; Grana, C.M.; Drozdov, I.; Cremonesi, M.; Lepensky, C.; Kwekkeboom, D.J.; Baum, R.P.; Krenning, E.P.; et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: The value and limitations of clinical factors. Eur. J. Nucl. Med. Mol. Imaging 2015, 42, 5–19. [Google Scholar] [CrossRef]
  3. Hamiditabar, M.; Ali, M.; Roys, J.; Wolin, E.M.; O’Dorisio, T.M.; Ranganathan, D.; Tworowska, I.; Strosberg, J.R.; Delpassand, E.S. Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years’ Assessment. Clin. Nucl. Med. 2017, 42, 436–443. [Google Scholar] [CrossRef]
  4. Yordanova, A.; Wicharz, M.M.; Mayer, K.; Brossart, P.; Gonzalez-Carmona, M.A.; Strassburg, C.P.; Fimmers, R.; Essler, M.; Ahmadzadehfar, H. The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy. Clin. Cancer Res. 2018, 24, 4672–4679. [Google Scholar] [CrossRef] [Green Version]
  5. Yordanova, A.; Ahrens, H.; Feldmann, G.; Brossart, P.; Gaertner, F.C.; Fottner, C.; Weber, M.M.; Ahmadzadehfar, H.; Schreckenberger, M.; Miederer, M.; et al. Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors. Clin. Nucl. Med. 2019, 44, e329–e335. [Google Scholar] [CrossRef]
  6. Paganelli, G.; Sansovini, M.; Nicolini, S.; Grassi, I.; Ibrahim, T.; Amadori, E.; Di Iorio, V.; Monti, M.; Scarpi, E.; Bongiovanni, A.; et al. (177)Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 152–160. [Google Scholar] [CrossRef]
  7. Sabet, A.; Dautzenberg, K.; Haslerud, T.; Aouf, A.; Sabet, A.; Simon, B.; Mayer, K.; Biersack, H.J.; Ezziddin, S. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Eur. J. Nucl. Med. Mol. Imaging 2015, 42, 1238–1246. [Google Scholar] [CrossRef]
  8. Ezziddin, S.; Opitz, M.; Attassi, M.; Biermann, K.; Sabet, A.; Guhlke, S.; Brockmann, H.; Willinek, W.; Wardelmann, E.; Biersack, H.J.; et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 459–466. [Google Scholar] [CrossRef]
  9. Delpassand, E.S.; Samarghandi, A.; Zamanian, S.; Wolin, E.M.; Hamiditabar, M.; Espenan, G.D.; Erion, J.L.; O’Dorisio, T.M.; Kvols, L.K.; Simon, J.; et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: The first US phase 2 experience. Pancreas 2014, 43, 518–525. [Google Scholar] [CrossRef] [Green Version]
  10. Hamiditabar, M.; Ali, M.; Bolek, L.; Vahdati, G.; Tworowska, I.; Delpassand, E.S. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors. Clin. Nucl. Med. 2017, 42, 822–828. [Google Scholar] [CrossRef]
  11. Foster, J.H.; Sher, A.; Seghers, V.; Poston, J.; Wells, D.; Delpassand, E.S.; Potter, S.; Mahajan, P.; Venkatramani, R. Peptide receptor radionuclide therapy for treatment of metastatic neuroendocrine tumors in children. Pediatr. Blood Cancer 2021, 68, e29056. [Google Scholar] [CrossRef]
  12. Braat, A.; Kwekkeboom, D.J.; Kam, B.L.R.; Teunissen, J.J.M.; de Herder, W.W.; Dreijerink, K.M.A.; van Rooij, R.; Krijger, G.C.; de Jong, H.; van den Bosch, M.; et al. Additional hepatic (166)Ho-radioembolization in patients with neuroendocrine tumours treated with (177)Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). BMC Gastroenterol. 2018, 18, 84. [Google Scholar] [CrossRef]
  13. Brabander, T.; van der Zwan, W.A.; Teunissen, J.J.M.; Kam, B.L.R.; Feelders, R.A.; de Herder, W.W.; van Eijck, C.H.J.; Franssen, G.J.H.; Krenning, E.P.; Kwekkeboom, D.J. Long-Term Efficacy, Survival, and Safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin. Cancer Res. 2017, 23, 4617–4624. [Google Scholar] [CrossRef] [Green Version]
  14. van Vliet, E.I.; van Eijck, C.H.; de Krijger, R.R.; Nieveen van Dijkum, E.J.; Teunissen, J.J.; Kam, B.L.; de Herder, W.W.; Feelders, R.A.; Bonsing, B.A.; Brabander, T.; et al. Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate. J. Nucl. Med. 2015, 56, 1647–1653. [Google Scholar] [CrossRef] [Green Version]
  15. Strosberg, J.; Krenning, E. 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N. Engl. J. Med. 2017, 376, 1391–1392. [Google Scholar] [CrossRef]
  16. van Essen, M.; Krenning, E.P.; Kam, B.L.; de Herder, W.W.; Feelders, R.A.; Kwekkeboom, D.J. Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J. Nucl. Med. 2010, 51, 383–390. [Google Scholar] [CrossRef] [Green Version]
  17. Sabet, A.; Haug, A.R.; Eiden, C.; Auernhammer, C.J.; Simon, B.; Bartenstein, P.; Biersack, H.J.; Ezziddin, S. Efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in metastatic pulmonary neuroendocrine tumors: A dual-centre analysis. Am. J. Nucl. Med. Mol. Imaging 2017, 7, 74–83. [Google Scholar]
  18. Ezziddin, S.; Khalaf, F.; Vanezi, M.; Haslerud, T.; Mayer, K.; Al Zreiqat, A.; Willinek, W.; Biersack, H.J.; Sabet, A. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 925–933. [Google Scholar] [CrossRef]
  19. Bodei, L.; Cwikla, J.B.; Kidd, M.; Modlin, I.M. The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors. J. Thorac. Dis. 2017, 9, S1511–S1523. [Google Scholar] [CrossRef] [Green Version]
  20. Hicks, R.J.; Kwekkeboom, D.J.; Krenning, E.; Bodei, L.; Grozinsky-Glasberg, S.; Arnold, R.; Borbath, I.; Cwikla, J.; Toumpanakis, C.; Kaltsas, G.; et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology 2017, 105, 295–309. [Google Scholar] [CrossRef]
  21. Albertelli, M.; Dotto, A.; Di Dato, C.; Malandrino, P.; Modica, R.; Versari, A.; Colao, A.; Ferone, D.; Faggiano, A.; Nike. PRRT: Identikit of the perfect patient. Rev. Endocr. Metab. Disord. 2021, 22, 563–579. [Google Scholar] [CrossRef]
  22. Ezziddin, S.; Attassi, M.; Yong-Hing, C.J.; Ahmadzadehfar, H.; Willinek, W.; Grunwald, F.; Guhlke, S.; Biersack, H.J.; Sabet, A. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J. Nucl. Med. 2014, 55, 183–190. [Google Scholar] [CrossRef] [Green Version]
  23. Kwekkeboom, D.J.; Kam, B.L.; van Essen, M.; Teunissen, J.J.; van Eijck, C.H.; Valkema, R.; de Jong, M.; de Herder, W.W.; Krenning, E.P. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr. Relat. Cancer 2010, 17, R53–R73. [Google Scholar] [CrossRef] [Green Version]
  24. Sabet, A.; Khalaf, F.; Yong-Hing, C.J.; Sabet, A.; Haslerud, T.; Ahmadzadehfar, H.; Guhlke, S.; Grunwald, F.; Biersack, H.J.; Ezziddin, S. Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement. Nuklearmedizin 2014, 53, 54–59. [Google Scholar] [CrossRef]
  25. Bergsma, H.; van Lom, K.; Raaijmakers, M.; Konijnenberg, M.; Kam, B.; Teunissen, J.J.M.; de Herder, W.W.; Krenning, E.P.; Kwekkeboom, D.J. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors. J. Nucl. Med. 2018, 59, 452–458. [Google Scholar] [CrossRef] [Green Version]
  26. Valkema, R.; Pauwels, S.A.; Kvols, L.K.; Kwekkeboom, D.J.; Jamar, F.; de Jong, M.; Barone, R.; Walrand, S.; Kooij, P.P.; Bakker, W.H.; et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J. Nucl. Med. 2005, 46 (Suppl. S1), 83–91. [Google Scholar]
  27. Sabet, A.; Ezziddin, K.; Pape, U.F.; Reichman, K.; Haslerud, T.; Ahmadzadehfar, H.; Biersack, H.J.; Nagarajah, J.; Ezziddin, S. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 505–510. [Google Scholar] [CrossRef]
  28. Bergsma, H.; Konijnenberg, M.W.; van der Zwan, W.A.; Kam, B.L.; Teunissen, J.J.; Kooij, P.P.; Mauff, K.A.; Krenning, E.P.; Kwekkeboom, D.J. Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate. Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 1802–1811. [Google Scholar] [CrossRef] [Green Version]
  29. Mangan, K.F. Peripheral blood stem cell transplantation: From laboratory to clinical practice. Semin. Oncol. 1995, 22, 202–209. [Google Scholar]
  30. Talmadge, J.E.; Reed, E.; Ino, K.; Kessinger, A.; Kuszynski, C.; Heimann, D.; Varney, M.; Jackson, J.; Vose, J.M.; Bierman, P.J. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant. 1997, 19, 161–172. [Google Scholar] [CrossRef] [Green Version]
  31. Siena, S.; Schiavo, R.; Pedrazzoli, P.; Carlo-Stella, C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J. Clin. Oncol. 2000, 18, 1360–1377. [Google Scholar] [CrossRef]
  32. Wuchter, P.; Ran, D.; Bruckner, T.; Schmitt, T.; Witzens-Harig, M.; Neben, K.; Goldschmidt, H.; Ho, A.D. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol. Blood Marrow Transplant. 2010, 16, 490–499. [Google Scholar] [CrossRef] [Green Version]
  33. Lemoli, R.M.; D’Addio, A. Hematopoietic stem cell mobilization. Haematologica 2008, 93, 321–324. [Google Scholar] [CrossRef] [Green Version]
  34. Kwekkeboom, D.J.; de Herder, W.W.; van Eijck, C.H.; Kam, B.L.; van Essen, M.; Teunissen, J.J.; Krenning, E.P. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin. Nucl. Med. 2010, 40, 78–88. [Google Scholar] [CrossRef]
  35. Forrer, F.; Uusijarvi, H.; Storch, D.; Maecke, H.R.; Mueller-Brand, J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J. Nucl. Med. 2005, 46, 1310–1316. [Google Scholar] [PubMed]
  36. Sabet, A.; Haslerud, T.; Pape, U.F.; Sabet, A.; Ahmadzadehfar, H.; Grunwald, F.; Guhlke, S.; Biersack, H.J.; Ezziddin, S. Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 205–210. [Google Scholar] [CrossRef] [PubMed]
  37. van der Zwan, W.A.; Brabander, T.; Kam, B.L.R.; Teunissen, J.J.M.; Feelders, R.A.; Hofland, J.; Krenning, E.P.; de Herder, W.W. Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 704–717. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Ezziddin, S.; Sabet, A.; Heinemann, F.; Yong-Hing, C.J.; Ahmadzadehfar, H.; Guhlke, S.; Holler, T.; Willinek, W.; Boy, C.; Biersack, H.J. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. J. Nucl. Med. 2011, 52, 1197–1203. [Google Scholar] [CrossRef] [Green Version]
  39. Bergsma, H.; Konijnenberg, M.W.; Kam, B.L.; Teunissen, J.J.; Kooij, P.P.; de Herder, W.W.; Franssen, G.J.; van Eijck, C.H.; Krenning, E.P.; Kwekkeboom, D.J. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: Prognostic factors, incidence and course. Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 453–463. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  40. Sabet, A.; Ezziddin, K.; Pape, U.F.; Ahmadzadehfar, H.; Mayer, K.; Poppel, T.; Guhlke, S.; Biersack, H.J.; Ezziddin, S. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J. Nucl. Med. 2013, 54, 1857–1861. [Google Scholar] [CrossRef] [Green Version]
  41. Fitzgerald, P.A.; Goldsby, R.E.; Huberty, J.P.; Price, D.C.; Hawkins, R.A.; Veatch, J.J.; Dela Cruz, F.; Jahan, T.M.; Linker, C.A.; Damon, L.; et al. Malignant pheochromocytomas and paragangliomas: A phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann. N. Y. Acad. Sci. 2006, 1073, 465–490. [Google Scholar] [CrossRef] [PubMed]
  42. Gerlach, L.O.; Skerlj, R.T.; Bridger, G.J.; Schwartz, T.W. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J. Biol. Chem. 2001, 276, 14153–14160. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Debnath, B.; Xu, S.; Grande, F.; Garofalo, A.; Neamati, N. Small molecule inhibitors of CXCR4. Theranostics 2013, 3, 47–75. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Pharmaceuticals 14 01022 g001 550
Figure 1. Maximum-intensity-projection 68Ga-DOTATOC PET images of a patient with renal NET before (A) and after (B) four cycles of 177Lu-DOTATATE (29 GBq) showing initial response. Repeat PRRT was performed 14 months later because of progressive disease (C) after successful PBSC harvesting and almost achieved disease stabilization (D) after 2 cycles (15.4 GBq) of re-PRRT and partial response (E) after additional 3 cycles (18 GBq).
Figure 1. Maximum-intensity-projection 68Ga-DOTATOC PET images of a patient with renal NET before (A) and after (B) four cycles of 177Lu-DOTATATE (29 GBq) showing initial response. Repeat PRRT was performed 14 months later because of progressive disease (C) after successful PBSC harvesting and almost achieved disease stabilization (D) after 2 cycles (15.4 GBq) of re-PRRT and partial response (E) after additional 3 cycles (18 GBq).
Pharmaceuticals 14 01022 g001
Table
Table 1. Patients’ characteristics and details of PBSC.
Table 1. Patients’ characteristics and details of PBSC.
Age/SexPrmary/GradePrevious TherapiesMetastatic SiteMobilizing AgentPBSC ResultsActivity (Cycles)Response
Before PBSCAfter PBSC
60y/wIleum/G2CTx (Dox/5FU), SSAliver, bone, LNG-CSFSuccessful0 GBq (0)43.0 GBq (6)SD
54y/wKidney/G2Surgery, SSA, PRRTboneG-CSFSuccessful29.0 GBq (4)33.4 GBq (5)PR
70y/mJejunum/G1Surgery, SSA, PRRTliver, boneG-CSF, PlerixaforSuccessful15.7 GBq (2)5.6 GBq (1)PD
53y/mCUP/G2CTx (Cis/5FU), Radiationliver, bone, LNG-CSFSuccessful0 GBq (0)39.0 GBq (6)PR
58y/wPancreas/G2CTx (STZ/5FU), SSA Surgery, PRRTliver, boneG-CSF, PlerixaforSuccessful37.3 GBq (5)7.5 GBq (1)PR
CUP, cancer of unknown origin; SSA, somatostatin receptor analogues; CTx, chemotherapy; STZ, streptozotocin; Dox, doxorubicin; Cis, cisplatin; 5FU, 5-fluorouracil; PRRT, peptide receptor radionuclide therapy.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Sabet, A.; Mader, N.; Bittenbring, J.T.; Khreish, F.; Grünwald, F.; Biersack, H.J.; Ezziddin, S. Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Pharmaceuticals 2021, 14, 1022. https://doi.org/10.3390/ph14101022

AMA Style

Sabet A, Mader N, Bittenbring JT, Khreish F, Grünwald F, Biersack HJ, Ezziddin S. Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Pharmaceuticals. 2021; 14(10):1022. https://doi.org/10.3390/ph14101022

Chicago/Turabian Style

Sabet, Amir, Nicolai Mader, Jörg Thomas Bittenbring, Fadi Khreish, Frank Grünwald, Hans Jürgen Biersack, and Samer Ezziddin. 2021. "Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE" Pharmaceuticals 14, no. 10: 1022. https://doi.org/10.3390/ph14101022

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop